Preeclampsia | Norton Healthcare

Indication: Preeclampsia

A Phase 2b/3a, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of AMAG-423, a Digoxin Immune Fab, in Antepartum Subjects with Severe Preeclampsia

Antepartum Subjects

Drug Study

Principal Investigator: Helen How, M.D., M.D.
Maternal Fetal Medicine

Sponsor: AMAG Pharmaceuticals, Inc.

Learn more at ClinicalTrials.gov

Email for more information: MFMResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.